Literature DB >> 17572861

Safety outcomes of Alteplase among acute ischemic stroke patients with special characteristics.

P N Sylaja1, Wei Dong, James C Grotta, Mary K Miller, Kristen Tomita, Scott Hamilton, Charles Semba, Michael D Hill.   

Abstract

BACKGROUND: Although tissue plasminogen activator (tPA) has been approved for use in acute ischemic stroke, concerns linger regarding its safety. We analyzed whether patients in special subgroups (i.e., age >70 years, baseline National Institute of Health Stroke Scale (NIHSS) score >20, diabetes, congestive heart failure (CHF), and of Hispanic origin) have a higher risk of symptomatic intracerebral hemorrhage (SICH) than patients without these characteristics.
METHODS: Four prospective observational studies of acute ischemic stroke patients treated within 3 h with Alteplase were identified and individual patient data were pooled for this analysis. These included the Standard Treatment with Alteplase to Reverse Stroke Study [STARS, N = 389], Epidemiology Study of Ischemic Stroke [ESIS, N = 236], University Of Texas Houston Stroke Study [UT, N = 241], and Canadian Activase For Stroke Effectiveness Study [CASES, N = 1100]. The risk of SICH was calculated for all patients and for each of five subgroups.
RESULTS: A total of 1966 patients were studied. Overall the risk of symptomatic ICH was 4.7% (95%CI, 3.8-5.8%) and the risk was similar among patients with and without each of the five characteristics. Patients with advanced age, baseline NIHSS score >20, CHF or diabetes had increased mortality and significantly lower rate of functional recovery.
CONCLUSIONS: The present study suggests that these specified subgroups of patients are not at increased risk of SICH after stroke thrombolysis compared to those without these characteristics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17572861     DOI: 10.1007/s12028-007-0018-8

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  18 in total

1.  Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience.

Authors:  I L Katzan; A J Furlan; L E Lloyd; J I Frank; D L Harper; J A Hinchey; J P Hammel; A Qu; C A Sila
Journal:  JAMA       Date:  2000-03-01       Impact factor: 56.272

2.  Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).

Authors:  V Larrue; R von Kummer R; A Müller; E Bluhmki
Journal:  Stroke       Date:  2001-02       Impact factor: 7.914

Review 3.  Ethnic disparities in stroke: epidemiology, acute care, and postacute outcomes.

Authors:  James P Stansbury; Huanguang Jia; Linda S Williams; W Bruce Vogel; Pamela W Duncan
Journal:  Stroke       Date:  2005-01-06       Impact factor: 7.914

4.  Differences in stroke between white, Hispanic, and Native American patients: the Barrow Neurological Institute stroke database.

Authors:  J L Frey; H K Jahnke; E W Bulfinch
Journal:  Stroke       Date:  1998-01       Impact factor: 7.914

5.  Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy.

Authors:  Peter U Heuschmann; Peter L Kolominsky-Rabas; Joachim Roether; Bjoern Misselwitz; Klaus Lowitzsch; Jan Heidrich; Peter Hermanek; Carsten Leffmann; Matthias Sitzer; Marcel Biegler; Hans-Joachim Buecker-Nott; Klaus Berger
Journal:  JAMA       Date:  2004-10-20       Impact factor: 56.272

6.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

7.  Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke.

Authors:  A M Demchuk; L B Morgenstern; D W Krieger; T Linda Chi; W Hu; T H Wein; R J Hardy; J C Grotta; A M Buchan
Journal:  Stroke       Date:  1999-01       Impact factor: 7.914

8.  Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group.

Authors: 
Journal:  Stroke       Date:  1997-11       Impact factor: 7.914

9.  Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2.

Authors:  J H Gurwitz; J M Gore; R J Goldberg; H V Barron; T Breen; A C Rundle; M A Sloan; W French; W J Rogers
Journal:  Ann Intern Med       Date:  1998-10-15       Impact factor: 25.391

10.  Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data.

Authors:  Glenn D Graham
Journal:  Stroke       Date:  2003-11-06       Impact factor: 7.914

View more
  4 in total

Review 1.  Intravenous thrombolytic therapy in acute ischemic stroke: The art and science of treatment decision making.

Authors:  P N Sylaja; Andrew M Demchuk
Journal:  Ann Indian Acad Neurol       Date:  2008-01       Impact factor: 1.714

Review 2.  Absolute and Relative Contraindications to IV rt-PA for Acute Ischemic Stroke.

Authors:  Jennifer E Fugate; Alejandro A Rabinstein
Journal:  Neurohospitalist       Date:  2015-07

3.  Impact of acute ischemic stroke treatment in patients >80 years of age: the specialized program of translational research in acute stroke (SPOTRIAS) consortium experience.

Authors:  Joshua Z Willey; Santiago Ortega-Gutierrez; Nils Petersen; Pooja Khatri; Andria L Ford; Natalia S Rost; Latisha K Ali; Nichole R Gonzales; Jose G Merino; Brett C Meyer; Randolph S Marshall
Journal:  Stroke       Date:  2012-07-12       Impact factor: 7.914

Review 4.  Individual participant data meta-analysis of prognostic factor studies: state of the art?

Authors:  Ghada Abo-Zaid; Willi Sauerbrei; Richard D Riley
Journal:  BMC Med Res Methodol       Date:  2012-04-24       Impact factor: 4.615

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.